Tirzepatide Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 2.5 mg / 0.5 mL, 5 mg / 0.5 mL

Reference Brands: Mounjaro (USA/EU), Zepbound (USA)

Category: Diabetes

Tirzepatide is a once-weekly injection that activates both GLP-1 and GIP receptors, for type 2 diabetes (Mounjaro) and weight management (Zepbound), at doses of 2.5 to 15 mg. It is made by Eli Lilly and remains under patent in most markets. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Tirzepatide is a novel, first-in-class dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, approved by the US FDA for the treatment of Type 2 diabetes mellitus (T2DM). By simultaneously activating both incretin pathways, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. This dual mechanism contributes to significant improvements in glycemic control and weight reduction, providing therapeutic benefits comparable to GLP-1 receptor agonists like semaglutide.

In addition to its use in T2DM, tirzepatide has shown substantial efficacy in weight management, making it a potential therapeutic option for obesity. It is administered as a subcutaneous injection once weekly, with doses titrated based on clinical response and tolerability. Clinical trials have demonstrated that tirzepatide is effective in reducing HbA1c, lowering fasting blood glucose, and promoting sustained weight loss, while maintaining a favorable safety profile.

Tirzepatide represents a significant advancement in metabolic therapy, offering dual benefits for glycemic control and weight management, and is an important treatment option for patients with T2DM, particularly those with obesity or cardiovascular risk factors.